Hidden Prescription Drug Prompts Nationwide Recall Of Joint Pain Supplement

The FDA announced a nationwide recall of Silintan joint pain supplements after testing found undeclared meloxicam, a ...
Monthly Prescribing Reference

Novel Meloxicam Formulation Reduces Postop Pain in Two Trials

A reduction in opioid usage over the entire treatment period was observed in patients treated with MR-107A-02 vs placebo. Topline data were announced from two phase 3 studies evaluating MR-107A-02 for ...
Seeking Alpha

Viatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain

In Both Acute Pain Models, MR-107A-02 Demonstrated Statistically Significant and Clinically Meaningful Improvement in Pain Compared to Placebo, Significant Reduction in Opioid Usage and Superior Pain ...